FrancophonIA/ELRC3.0 huggingface dataset:
English: Do not use in cases of impaired kidney or liver function.
Slovenian: Ne uporabite v primeru motenega delovanje ledvic ali jeter.
English: To avoid accidental ingestion administer the tablet to the dog immediately after removal from the blister packaging.
Slovenian: Da se izognete možnosti nenamernega zaužitja, dajte tableto psu takoj, ko jo odstranite iz pretisnega omota.
English: There is no specific antidote for mavacoxib overdose, but general supportive therapy, as applied to clinical overdosewith NSAIDs, should be given.
Slovenian: Za preveliko odmerjanje mavakoksiba ni specifičnega antidota ampak se uporabi splošna podporna terapija, kot pri vseh prevelikih odmerjanjih nesteroidnih protivnetnih zdravil.
English: Mavacoxib possessed a longer elimination half-life in clientowned animals.
Slovenian: Mavakoksib je imel daljši razpolovni čas pri psih, ki so bili v lasti strank.
English: In common with other NSAIDs, Trocoxil should not be administered simultaneously with other NSAIDs or glucocorticosteroids.
Slovenian: Kot pri drugih nesteroidnih protivnetnih zdravilih, naj se Trocoxila ne uporablja istočasno z drugimi nesteroidnim protivnetnimi zdravili ali glukokortikosteroidi.
English: The rate of body clearance of mavacoxib is slow and the major route of elimination is by biliary excretion of the parent drug.
Slovenian: Stopnja izločanja mavakoksiba iz telesa je počasna, največ se izloči preko žolča kot izvorno zdravilo.
English: Animals should undergo a thorough clinical examination before commencing treatment with Trocoxil and appropriate laboratory tests to monitor haematology and clinical chemistry are recommended.
Slovenian: Pred zdravljenjem s Trocoxilom je potrebno pri živalih opraviti temeljit klinični pregled, priporočjivo je opraviti tudi ustrezne hematološke in biokemične preiskave.
English: Do not use concomitantly with glucocorticoids or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
Slovenian: Ne uporabite istočasno z glukokortikoidi ali drugimi nesteroidnimi protivnetnimi zdravili.
English: Blister packs containing two tablets of the same strength per pack, each tablet containing 6 mg, 20 mg, 30 mg, 75 mg or 95 mg of mavacoxib.
Slovenian: Pretisni omoti vsebujejo 2 tableti iste jakosti v vsakem pakiranju, vsaka tableta vsebuje 6 mg, 20 mg, 30 mg, 75 mg ali 95 mg mavakoksiba.
English: Chewable tablets
Slovenian: Žvečljive tablete.
English: Number and Strength of Tablets to be Administered
Slovenian: Število in jakost odmerjenih tablet
English: To avoid such effects when Trocoxil is to be administered in replacement of another NSAID, ensure an appropriate treatment-free period of at least 24 hours before administering the first dose of Trocoxil.
Slovenian: Ko boste uporabili Trocoxil kot zamenjavo za drugo nesteroidno protivnetno terapijo, zagotovite primeren čas brez zdravljenja vsaj 24 ur pred dajanjem prvega odmerka Trocoxila, da bi se izognili pojavu teh neželenih učinkov.
English: In case of accidental self-ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Slovenian: V primeru nenamernega zaužitja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali ovojnino.
English: Adverse reactions of the digestive tract such as vomiting and diarrhoea were commonly reported, loss of appetite, haemorrhagic diarrhoea and melaena have been reported in uncommon cases.
Slovenian: Pogosto so poročali o neželenih učinkih na prebavila kot sta bruhanje in driska, občasno pa o izgubi apetita, hemoragični driski in meleni.
English: Do not administer other NSAIDs or glucocorticoids concurrently or within at least 1 month of the last administration of Trocoxil.
Slovenian: Ne dajajte drugih nesteroidnih protivnetnih zdravil ali glukokortikoidov istočasno ali najmanj 1 mesec po zadnjem dajanju Trocoxila.
English: These IC concentrations may be compared with mean trough concentrations of mavacoxib in plasma in clinical subjects of 0.52 and 1.11 µg/mL, respectively, after the first and fifth doses.
Slovenian: IC koncentracije se lahko primerjajo z povprečnimi koncentracijami mavakoksiba v plazmi pri kliničnih primerih z 0,52 in 1,11 µg/ml, po prvem in petem odmerku, zato se predvideva, da bodo klinični odmerki ustvarili nizek nivo inhibicije COX-1 in visok nivo inhibicije COX-2.
English: The veterinary medicinal product does not require any special storage conditions.
Slovenian: Za shranjevanje ni posebnih navodil.
English: Mavacoxib is excreted via bile and in dogs with hepatic disorders reduced elimination and thus excessive accumulation could occur.
Slovenian: Pri psih z motnjami v delovanju jeter je lahko eliminacija zmanjšana, posledično se pojavi akumulacija.
English: Each blister contains two tablets of 6 mg, 20 mg, 30 mg, 75 mg or 95 mg mavacoxib, respectively.
Slovenian: Vsak pretisni omot vsebuje dve tableti s po 6 mg, 20 mg, 30 mg, 75 mg ali 95 mg mavakoksiba.
English: Dogs should be carefully monitored if Trocoxil is administered simultaneously with an anticoagulant.
Slovenian: Če je Trocoxil apliciran skupaj z antikoagulantom, je potrebno psa pozorno nadzorovati.
English: It is extensively distributed throughout the body and almost all the mavacoxib-related residues in plasma comprise parent drug.
Slovenian: Mavakoksib se v okoli 98 % veže na plazemske proteine, se obsežno razporedi po vsem organizmu in skoraj vsi mavakoksibu sorodni ostanki v plazmi vključujejo izvirno zdravilo.
English: Do not administer other NSAIDs or glucocorticoids concurrently or within 1 month of the last administration of Trocoxil.
Slovenian: Ne dajajte drugih nesteroidnih protivnetnih zdravil ali glukokortikoidov sočasno ali 1 mesec po zadnjem dajanju Trocoxila.
English: Do not use where there is evidence of a haemorrhagic disorder.
Slovenian: Ne uporabite pri znakih hemoragičnih motenj.
English: Trocoxil 6 mg chewable tablets for dogs Trocoxil 20 mg chewable tablets for dogs Trocoxil 30 mg chewable tablets for dogs Trocoxil 75 mg chewable tablets for dogs Trocoxil 95 mg chewable tablets for dogs
Slovenian: Trocoxil 6 mg žvečljive tablete za pse Trocoxil 20 mg žvečljive tablete za pse Trocoxil 30 mg žvečljive tablete za pse Trocoxil 75 mg žvečljive tablete za pse Trocoxil 95 mg žvečljive tablete za pse
English: Do not use in pregnant, breeding or lactating dogs.
Slovenian: Ne uporabite pri brejih, vzrejnih psicah ali psicah v laktaciji.
English: Trocoxil 6 mg chewable tablets for dogs Trocoxil 20 mg chewable tablets for dogs Trocoxil 30 mg chewable tablets for dogs Trocoxil 75 mg chewable tablets for dogs Trocoxil 95 mg chewable tablets for dogs Mavacoxib
Slovenian: Trocoxil 6 mg žvečljive tablete za pse Trocoxil 20 mg žvečljive tablete za pse Trocoxil 30 mg žvečljive tablete za pse Trocoxil 75 mg žvečljive tablete za pse Trocoxil 95 mg žvečljive tablete za pse Mavakoksib
English: If an adverse reaction following the administration of Trocoxil occurs, no further tablets should be administered and general supportive therapy, as applied to clinical overdose with NSAIDs, should be applied.
Slovenian: Če se pojavijo neželeni učinki po dajanju Trocoxila, se prekine nadaljnje dajanje tablet in se začne s splošno podporno terapijo, ki je primerna za klinično preveliko odmerjanje nesteroidnih protivnetnih zdravil.
English: Mavacoxib exhibits an extended plasma half life (up to > 80 days, see section 5.2) due to its low rate of elimination.
Slovenian: Mavakoksib ima zaradi svoje nizke stopnje eliminacije podaljšan razpolovni čas v plazmi (do > 80 dni, glejte poglavje 5.2) To sovpada s trajanjem učinkovanja 1-2 meseca po dajanju drugega odmerka (in sledečih odmerkov).
English: Patients with underlying renal disease may experience exacerbation or decompensation of their renal disease while on NSAID therapy.
Slovenian: Pri živalih s prikrito boleznijo ledvic lahko med zdravljenjem z nesteroidnimi protivnetnimi zdravili pride do poslabšanja ali dekompenzacije ledvične bolezni (glejte tudi poglavje 4.6)
English: Multiple-dose pharmacokinetic studies provided no evidence that mavacoxib produces autoinhibition or autoinductive changes in its clearance, and it exhibits linear pharmacokinetics with oral doses ranging from 2 to 50 mg/kg.
Slovenian: Farmakokinetične študije z več odmerki niso pokazale, da bi mavakoksib povzročal avto inhibicijo ali avto induktivne spremembe pri svojem izločanju.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each chewable tablet contains:
Slovenian: KAKOVOSTNA IN KOLIČINSKA SESTAVA
English: Apathy, degradation of renal biochemistry parameters and impaired renal function have been reported in uncommon cases.
Slovenian: Občasno so poročali o apatiji, spremembah biokemičnih ledvičnih parametrov in poslabšanem delovanju ledvic.
English: Do not use in pregnant, breeding or lactating animals.
Slovenian: Ne uporabite pri brejih, vzrejnih živalih ali živalih v laktaciji.
English: Mavacoxib acts by preferential inhibition of COX-2-mediated prostaglandin synthesis.
Slovenian: Mavakoksib deluje kor preferenčni inhibitor COX-2 mediatorja pri sintezi prostaglandinov zato ima lastnosti analgetika in protivnetnega zdravila.
English: Carton
Slovenian: Zloženka
English: PACKAGE LEAFLET:
Slovenian: Ena žvečljiva tableta vsebuje:
English: Concurrent administration of potentially nephrotoxic medicinal products should be avoided.
Slovenian: Izogibajte se sočasni uporabi potencialno nefrotoksičnih zdravil.
English: Ingestion of Trocoxil may be harmful for children, and prolonged pharmacological effects leading to e.g. gastrointestinal disorders may be observed.
Slovenian: Zaužitje zdravila Trocoxil je lahko škodljivo za otroke.
English: Gastrointestinal protectants and parenteral fluids, as appropriate, may be required for animals that experienced gastrointestinal or renal adverse reactions.
Slovenian: Živali z neželenimi učinki na prebavila ali ledvice bo morda treba zdraviti z zdravili za zaščito sluznice prebavil oziroma parenteralnim nadomeščanjem tekočine.
English: MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Slovenian: Imetnik dovoljenja za promet z zdravilom in proizvajalec odgovoren za sproščanje serij:Zoetis Belgium SA
English: STATEMENT OF THE MRLs
Slovenian: C. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL)
English: Date of first authorisation: 21 March 2007 Date of latest renewal: 20 January 2012
Slovenian: Datum prve odobritve: 21. marec 2007 Datum zadnjega podaljšanja: 20. januar 2012
English: STOP taking Xelevia and contact a doctor immediately if you notice any of the following serious side effects:
Slovenian: Zdravilo Xelevia takoj PRENEHAJTE jemati in se posvetujte z zdravnikom, če opazite katerega koli od naslednjih resnih neželenih učinkov:
English: Do not take Xelevia - if you are allergic to sitagliptin or any of the other ingredients of this medicine (listed in section 6).
Slovenian: Ne jemljite zdravila Xelevia - če ste alergični na sitagliptin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: What Xelevia is and what it is used for
Slovenian: Kaj je zdravilo Xelevia in za kaj ga uporabljamo
English: Xelevia should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
Slovenian: Zdravila Xelevia se ne sme uporabljati pri bolnikih s sladkorno boleznijo tipa 1 ali za zdravljenje diabetične ketoacidoze.
English: Your doctor may ask you to stop Xelevia.
Slovenian: Zdravnik vam bo morda naročil, da prenehate z jemanjem zdravila Xelevia.
English: Other medicines and Xelevia
Slovenian: Druga zdravila in zdravilo Xelevia
English: Due to lack of human data, Xelevia should not be used during pregnancy.
Slovenian: Zaradi pomanjkanja podatkov pri ljudeh se zdravila Xelevia med nosečnostjo ne sme jemati.
English: If you take more Xelevia than you should If you take more than the prescribed dosage of this medicine, contact your doctor immediately.
Slovenian: Če ste vzeli večji odmerek zdravila Xelevia, kot bi smeli Če ste vzeli večji odmerek tega zdravila od predpisanega, se takoj posvetujte z zdravnikom.
English: What you need to know before you take Xelevia
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Xelevia
English: Rates of Composite Cardiovascular Outcomes and Key Secondary Outcomes sitagliptin 100 mg
Slovenian: Deleži sestavljenih srčno-žilnih izidov in ključnih sekundarnih izidov sitagliptin 100 mg placebo
English: For adult patients with type 2 diabetes mellitus, Xelevia is indicated to improve glycaemic control:
Slovenian: Pri odraslih bolnikih s sladkorno boleznijo tipa 2 je zdravilo Xelevia indicirano za izboljšanje urejenosti glikemije:
English: What Xelevia is and what it is used for What you need to know before you take Xelevia How to take Xelevia
Slovenian: Kaj je zdravilo Xelevia in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Xelevia Kako jemati zdravilo Xelevia Možni neželeni učinki
English: When used in combination with metformin and/or a PPAR agonist, the dose of metformin and/or PPAR agonist should be maintained, and Xelevia administered concomitantly.
Slovenian: Pri uporabi v kombinaciji z metforminom in/ali agonistom PPAR je treba odmerek metformina in/ali agonista PPAR ohraniti in zdravilo Xelevia uporabljati sočasno.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with Xelevia in one or more subsets of the paediatric population in type 2 diabetes mellitus (see section 4.2 for information on paediatric use).
Slovenian: Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij z zdravilom Xelevia za vse skupine pediatrične populacije za sladkorno bolezen tipa 2 (za podatek o uporabi pri pediatrični populaciji glejte poglavje 4.2).
English: What Xelevia looks like and contents of the pack
Slovenian: Izgled zdravila Xelevia in vsebina pakiranja
English: If you forget to take Xelevia
Slovenian: Če ste pozabili vzeti zdravilo Xelevia
English: Because there is a dosage adjustment based upon renal function, assessment of renal function is recommended prior to initiation of Xelevia and periodically thereafter.
Slovenian: Ker prilagoditev odmerka temelji na ledvični funkciji, pred začetkom zdravljenja z zdravilom Xelevia in periodično tekom zdravljenja priporočamo oceno ledvične funkcije.
English: Hypoglycaemia when used in combination with other anti-hyperglycaemic medicinal products In clinical trials of Xelevia as monotherapy and as part of combination therapy with medicinal products not known to cause hypoglycaemia (i.e. metformin and/or a PPAR agonist), rates of hypoglycaemia reported with sitagliptin were similar to rates in patients taking placebo.
Slovenian: Hipoglikemija pri zdravljenju v kombinaciji z ostalimi antihiperglikemiki V kliničnih preskušanjih zdravila Xelevia kot samostojnega zdravila in v kombinaciji z drugimi zdravili za katere ni znano, da povzročijo hipoglikemijo (tj. metforminom in/ali agonistom PPAR), so pri bolnikih, ki so jemali sitagliptin, poročali o podobnih deležih hipoglikemije kot pri bolnikih, ki so jemali placebo.
English: If you stop taking Xelevia
Slovenian: Če ste prenehali jemati zdravilo Xelevia
English: Since co-administration of a high-fat meal with sitagliptin had no effect on the pharmacokinetics, Xelevia may be administered with or without food.
Slovenian: Sočasno zaužitje sitagliptina ter obroka z veliko maščobami ni vplivalo na farmakokinetiko, zato se zdravilo Xelevia lahko jemlje s hrano ali brez nje.
English: Xelevia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
Slovenian: Zdravilo Xelevia je indicirano tudi kot dodatno zdravljenje k insulinu (z metforminom ali brez), če z dieto in s telesno aktivnostjo ter stabilnim odmerkom insulina urejenost glikemije ni zadostna.
English: For patients with severe renal impairment (GFR ≥ 15 to <30 mL/min) or with end-stage renal disease (ESRD) (GFR < 15 mL/min), including those requiring haemodialysis or peritoneal dialysis, the dose of Xelevia is 25 mg once daily.
Slovenian: Pri bolnikih s hudo ledvično okvaro (GFR ≥ 15 do < 30 ml/min) ali bolnikih s končno ledvično odpovedjo (ESRD - end-stage renal disease) (GFR < 15 ml/min), vključno s tistimi, ki potrebujejo hemodializo ali peritonealno dializo, je odmerek zdravila Xelevia 25 mg enkrat na dan.
English: Xelevia has not been studied in patients with severe hepatic impairment and care should be exercised (see section 5.2).
Slovenian: Pri bolnikih s hudo jetrno okvaro uporaba zdravila Xelevia ni raziskana, zato je potrebna previdnost (glejte poglavje 5.2).
English: If a dose of Xelevia is missed, it should be taken as soon as the patient remembers.
Slovenian: Če bolnik izpusti odmerek zdravila Xelevia, ga mora vzeti takoj, ko se spomni.
English: Method of administration Xelevia can be taken with or without food.
Slovenian: Način uporabe Zdravilo Xelevia lahko bolnik jemlje skupaj s hrano ali brez nje.
English: When Xelevia is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia (see section 4.4).
Slovenian: Pri uporabi zdravila Xelevia v kombinaciji s sulfonilsečnino ali z insulinom lahko po potrebi zmanjšate odmerek sulfonilsečnine ali insulina, da se tako zmanjša tveganje za pojav hipoglikemije (glejte poglavje 4.4).
English: Xelevia has no or negligible influence on the ability to drive and use machines.
Slovenian: Zdravilo Xelevia nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
English: How to take Xelevia
Slovenian: Kako jemati zdravilo Xelevia
English: Cases of inflammation of the pancreas (pancreatitis) have been reported in patients receiving Xelevia (see section 4).
Slovenian: Pri bolnikih, ki so prejemali zdravilo Xelevia, so poročali o primerih vnetja trebušne slinavke (pankreatitisa) (glejte poglavje 4).
English: For patients with moderate renal impairment (GFR  30 to < 45 mL/min), the dose of Xelevia is 50 mg once daily.
Slovenian: Pri bolnikih z zmerno ledvično okvaro (GFR ≥ 30 do < 45 ml/min) je odmerek zdravila Xelevia 50 mg enkrat na dan.
English: It is important to stay on the diet and exercise recommended by your doctor while taking Xelevia.
Slovenian: Med jemanjem zdravila Xelevia je pomembno, da se držite diete in telesne aktivnosti, ki vam ju je priporočil zdravnik.
English: Neopharmed Gentili S.p.A. Tel: +39 02891321 regulatory@neogen.it
Slovenian: Tel: +39 02891321 regulatory@neogen.it
English: What Xelevia contains
Slovenian: Kaj vsebuje zdravilo Xelevia
English: Xelevia is a member of a class of oral anti-hyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors.
Slovenian: Zdravilo Xelevia spada v skupino peroralnih antidiabetikov, imenovanih zaviralci dipeptidil peptidaze 4 (DPP-4).
English: Compared to normal healthy control subjects, plasma AUC of sitagliptin was increased by approximately 1.2-fold and 1.6-fold in patients with mild renal impairment (GFR ≥ 60 to
Slovenian: V primerjavi z zdravimi kontrolnimi preiskovanci je bila plazemska AUC sitagliptina pri bolnikih z blago ledvično okvaro (GFR ≥ 60 do < 90 ml/min) približno 1,2-krat večja, pri bolnikih z zmerno ledvično okvaro (GFR ≥ 45 do < 60 ml/min) pa približno 1,6-krat večja.
English: If a hypersensitivity reaction is suspected, Xelevia should be discontinued.
Slovenian: Če obstaja sum na preobčutljivostno reakcijo, morate prenehati zdravljenje z zdravilom Xelevia.
English: Xelevia should not be used during breast-feeding.
Slovenian: Med dojenjem se zdravila Xelevia ne sme jemati.
English: The level of digoxin in your blood may need to be checked if taking with Xelevia.
Slovenian: Med sočasnim jemanjem z zdravilom Xelevia vam bodo morda morali preveriti vrednosti digoksina v krvi.
English: Xelevia contains the active substance sitagliptin which is a member of a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) that lowers blood sugar levels in adult patients with type 2 diabetes mellitus.
Slovenian: Zdravilo Xelevia vsebuje učinkovino sitagliptin, ki spada v skupino zdravil, imenovano zaviralci DPP-4 (zaviralci dipeptidil peptidaze 4).
English: Xelevia 25 mg tablets Sitagliptin
Slovenian: Xelevia 25 mg tablete sitagliptin
English: If pancreatitis is suspected, Xelevia and other potentially suspect medicinal products should be discontinued; if acute pancreatitis is confirmed, Xelevia should not be restarted.
Slovenian: Ob sumu na pankreatitis je treba prenehati z jemanjem zdravila Xelevia in drugih zdravil, ki bi lahko povzročila pankreatitis.
English: Xelevia 100 mg tablets Sitagliptin
Slovenian: Xelevia 100 mg tablete sitagliptin
English: - type 1 diabetes - diabetic ketoacidosis (a complication of diabetes with high blood sugar, rapid weight loss,
Slovenian: - sladkorno bolezen tipa 1 - diabetično ketoacidozo (zaplet sladkorne bolezni z visokim krvnim sladkorjem, hitrim hujšanjem, siljenjem na bruhanje ali bruhanjem) - kakršne koli težave z ledvicami v sedanjosti ali v preteklosti - alergijsko reakcijo na zdravilo Xelevia (glejte poglavje 4)
English: No dose adjustment for Xelevia is necessary for patients with mild or moderate hepatic impairment (Child-Pugh score  9).
Slovenian: Pri bolnikih z blago ali zmerno jetrno okvaro (ocena po Child-Pugh-u  9) odmerka ni treba prilagoditi.
English: In addition, patients should be alerted to the risk of hypoglycaemia when Xelevia is used in combination with a sulphonylurea or with insulin.
Slovenian: Poleg tega je treba bolnike, ki jemljejo zdravilo Xelevia skupaj s sulfonilsečnino ali z insulinom, opozoriti na tveganje za pojav hipoglikemije.
English: Xelevia 50 mg tablets Sitagliptin
Slovenian: Xelevia 50 mg tablete sitagliptin
English: Marketing Authorisation Holder Merck Sharp & Dohme B.V. Waarderweg 39
Slovenian: Imetnik dovoljenja za promet z zdravilom: Merck Sharp & Dohme B.V.
English: Skin and subcutaneous tissue disorders pruritus
Slovenian: Bolezni kože in podkožja pruritus občasni angioedem neznana pogostnost
English: EU/1/07/382/013 14 film-coated tablets EU/1/07/382/014 28 film-coated tablets EU/1/07/382/023 30 film-coated tablets EU/1/07/382/015 56 film-coated tablets EU/1/07/382/016 84 film-coated tablets EU/1/07/382/024 90 film-coated tablets EU/1/07/382/017 98 film-coated tablets EU/1/07/382/018 50 x 1 film-coated tablets
Slovenian: EU/1/07/382/013 14 filmsko obloženih tablet EU/1/07/382/014 28 filmsko obloženih tablet EU/1/07/382/023 30 filmsko obloženih tablet EU/1/07/382/015 56 filmsko obloženih tablet EU/1/07/382/016 84 filmsko obloženih tablet EU/1/07/382/024 90 filmsko obloženih tablet EU/1/07/382/017 98 filmsko obloženih tablet EU/1/07/382/018 50 x 1 filmsko obložena tableta
English: EU/1/07/382/007 14 film-coated tablets EU/1/07/382/008 28 film-coated tablets EU/1/07/382/021 30 film-coated tablets EU/1/07/382/009 56 film-coated tablets EU/1/07/382/010 84 film-coated tablets EU/1/07/382/022 90 film-coated tablets EU/1/07/382/011 98 film-coated tablets EU/1/07/382/012 50 x 1 film-coated tablets
Slovenian: EU/1/07/382/007 14 filmsko obloženih tablet EU/1/07/382/008 28 filmsko obloženih tablet EU/1/07/382/021 30 filmsko obloženih tablet EU/1/07/382/009 56 filmsko obloženih tablet EU/1/07/382/010 84 filmsko obloženih tablet EU/1/07/382/022 90 filmsko obloženih tablet EU/1/07/382/011 98 filmsko obloženih tablet EU/1/07/382/012 50 x 1 filmsko obložena tableta
English: How to store Xelevia
Slovenian: Shranjevanje zdravila Xelevia
English: Xelevia 25 mg film-coated tablets Sitagliptin
Slovenian: Xelevia 25 mg filmsko obložene tablete sitagliptin
English: EU/1/07/382/001 14 film-coated tablets EU/1/07/382/002 28 film-coated tablets EU/1/07/382/019 30 film-coated tablets EU/1/07/382/003 56 film-coated tablets EU/1/07/382/004 84 film-coated tablets EU/1/07/382/020 90 film-coated tablets EU/1/07/382/005 98 film-coated tablets EU/1/07/382/006 50 x 1 film-coated tablets
Slovenian: EU/1/07/382/001 14 filmsko obloženih tablet EU/1/07/382/002 28 filmsko obloženih tablet EU/1/07/382/019 30 filmsko obloženih tablet EU/1/07/382/003 56 filmsko obloženih tablet EU/1/07/382/004 84 filmsko obloženih tablet EU/1/07/382/020 90 filmsko obloženih tablet EU/1/07/382/005 98 filmsko obloženih tablet EU/1/07/382/006 50 x 1 filmsko obložena tableta